Orchid Pharma Limited announced that its board approved a proposal to raise up to Rs 600 crore through a qualified institutions placement, private placement, public issue of equity shares, debt securities, preferential issue, or a combination of these modes, potentially including fully or partly convertible debentures. The fund raising will be subject to statutory and regulatory approvals, including shareholder approval, and the specific details regarding the type of securities, pricing, and number of securities will be disclosed at a later date. The board also explored potential market opportunities and approved an enabling resolution for this purpose.